Strengthen Your Product Value Story One Phase at a Time

August 23, 2017

Addressing evidence generation in a phase-specific manner provides mutually reinforcing benefits: trials contribute to the value argument and the value data inform the design of the trials. In this way, utilizing the best available secondary research to inform primary research can reduce the risk of regulatory and reimbursement rejections.

A phase-dependent approach has potential to cut costs by avoiding investing in riskier assets, utilizing secondary evidence for multiple assets (thereby using resources more efficiently), and creating payer value while simultaneously meeting regulatory requirements.

The best way to plan evidence generation for the value story is from the beginning. But if you didn’t do that already, the sooner you start the better.

 

Previous Flipbook
LIQUENT INSIGHT®: The Right Choice for Regulatory Information Management
LIQUENT INSIGHT®: The Right Choice for Regulatory Information Management

Read why 18 of the top 20 pharmaceutical companies are using a module of the LIQUENT InSight® platform as t...

Next Flipbook
The Path to Better Trial Design
The Path to Better Trial Design

To strike a balance between rigor and cost-effectiveness, trials must be right-sized and the mistakes of th...

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!